AUTHORS
Surbhi Sidana, MD, Danai Dima, MD2, Alexandria Jensen, Phd3, M Bakri Hammami, MD4, Andrew Jay Portuguese, MD5, Robert Mina6, Lekha Mikkilineni, MD, MA7, Nishi Shah, MD, MPH8, Emily C. Liang, MD9, Vanna Hovanky10, Masooma Shifa Rana, MBBS11, Sara Ann Scott, PharmD, BCOP12, Richa Parikh, MD13, Hyma Vempaty14, Blanca Lopez15, Christina Copponex16, Hana Qasim, Fellow17, Ryan Basom18, Christy Khouderchah19, Omar Puglianini, MD20, Shuchita Kaila, PhD21, Zaina Qureshi, PHD22, Saurabh P. Nagar23, Victoria Alegria, MD24, Kevin De Braganca, MD25, Mukta Sharma, MD, MPH26, Vicki Plaks27, Jinzhou Yuan28, Matthew Perciavalle, PharmD29, Madhav V. Dhodapkar, MD30, David Miklos, MD, PhD31, Ajay K Nooka, MD, MPH32, Rahul Banerjee, MD33, Jonathan L Kaufman, MD34, Melissa Alsina, MD35, Nisha Joseph, MD36, Doris K. Hansen, MD37
AFFILIATIONS
1 Stanford University School of Medicine, Palo Alto, California, United States
2 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
3 Stanford University School of Medicine, Palo Alto, California, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
6 Winship at Emory University Hospital Midtown, Atlanta, Georgia, United States
7 Stanford University School of Medicine, Palo Alto, California, United States
8 Winship at Emory University Hospital Midtown, Atlanta, Georgia, United States
9 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
10 Stanford University School of Medicine, Palo Alto, California, United States
11 Stanford University School of Medicine, Palo Alto, California, United States
12 Winship at Emory University Hospital Midtown, Atlanta, Georgia, United States
13 Winship at Emory University Hospital Midtown, Atlanta, Georgia, United States
14 Stanford University School of Medicine, Palo Alto, California, United States
15 Moffitt Cancer Center, Tampa, Florida, United States
16 Moffitt Cancer Center, Tampa, Florida, United States
17 Moffitt Cancer Center, Tampa, Florida, United States
18 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
19 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
20 Moffitt Cancer Center, Tampa, Florida, United States
21 Johnson and Johnson, Horsham, United States
22 Johnson and Johnson, Horsham, United States
23 Johnson and Johnson, Horsham, United States
24 Johnson and Johnson, Horsham, United States
25 Johnson and Johnson, Horsham, United States
26 Johnson and Johnson, Horsham, United States
27 Johnson and Johnson, Horsham, United States
28 Johnson and Johnson, Horsham, United States
29 Legend Biotech, Bridgewater, United States
30 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
31 Stanford University School of Medicine, Palo Alto, California, United States
32 Winship at Emory University Hospital Midtown, Atlanta, Georgia, United States
33 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
34 Winship at Emory University Hospital Midtown, Atlanta, Georgia, United States
35 Moffitt Cancer Center, Tampa, Florida, United States
36 Winship at Emory University Hospital Midtown, Atlanta, Georgia, United States
37 Moffitt Cancer Center, Tampa, Florida, United States
ABSTRACT
Introduction: Cilta-cel produces durable responses in RRMM; however, rare, serious side effects such as non-ICANS neurotoxicity (NINT), including immune effector cell associated Parkinsonism (IEC-PKS), remain a challenge. Rapid, high CAR-T expansion increases risk of IEC-PKS, with absolute lymphocyte count (ALC) serving as a surrogate for CAR expansion (Hosoya et al Blood 2026). ALC≥ 3000/uL has been associated with increased PKS risk (12%; Sidana et al ASH 2025, Lim et al BCJ 2025). Based on the strong association of cilta-cel expansion with NINT, we designed CITADEL, a multi-center observational study at 4 US academic centers to evaluate risk mitigation measures for preventing IEC-PKS.
Methods: We implemented a prophylactic dexamethasone strategy (prophy dex), with dex given as either 10 mg BID or 20 mg daily for a minimum of 3 days for elevated ALC count ≥3000/uL occurring during the 1st month after cilta-cel infusion. Steroids could be modified or continued longer per treating physician discretion. By June 2025, prophy dex was implemented at all 4 participating centers. Data on safety and efficacy outcomes with cilta-cel were collected for all consecutive patients (pts) treated from June-Dec 2025.The primary endpoint of the study was the incidence of IEC-PKS. Secondary endpoints were other safety and efficacy outcomes.
Results: 185 pts received cilta-cel during the study period. The median age was 65 yrs; 55% had high-risk cytogenetics and 15% had extramedullary disease (EMD). Median prior lines of therapy (LOT) were 3 (range 1-8), and 59% of pts had received 1-3 prior LOT. Bridging therapy was given to 94%, with ≥PR observed in 44% of pts. All pts alive at data cutoff had ≥3 months of follow-up. CRS occurred in 64% (G≥2: 14%) and ICANS in 8% (G≥2: 1%). ORR and CR rates were 94% and 61%, respectively.
Prophy dex was used in 43% (n=80) of pts. Baseline characteristics, response rates, PFS, CRS and ICANS rates were similar between pts receiving prophy dex vs not. Post cilta-cel peak ALC was higher in the prophy dex group (median: 4940 vs 1735/uL), while other labs including peak ferritin, CRP, and platelet count were similar. ALC decreased to <3000/uL in 81% of pts with prophy dex.
Overall, 1.6% of pts (n=3) developed IEC-PKS and 24 (13%) developed other NINT, mainly CN VII palsy. All 3 pts who developed IEC-PKS had ALC≥3000/uL and received prophy dex. Pre-lymphodepletion (LD) ferritin was significantly higher in pts with IEC-PKS vs other NINT vs no NINT (2220 vs 98 vs 132 ng/mL, p<0.001). Pre-apheresis and pre-LD albumin were lower, whereas pre-apheresis and pre-LD beta-2-microglobulin (B2M) and pre-LD LDH were numerically higher amongst pts with IEC-PKS vs not. While 2 of 3 pts with IEC-PKS had PR to bridging therapy, all had significant residual disease at pre-LD (M-spike>1 g/dL or iFLC>100 mg/L). All 3 IEC-PKS pts had high-risk cytogenetics and 1 had EMD. There were no other differences in baseline characteristics of pts with vs without IEC-PKS.
Median peak ALC was higher in pts with IEC-PKS: 16600/uL (range 3460-55190) vs other NINT (5420) vs no NINT (2340). Following prophy dex, median ALC was 4550 vs 1720 vs 1120/uL, respectively; ALC decreased to <3000/uL in nearly all pts in the no NINT or other NINT groups but persisted ≥3000/uL in 2 of 3 pts with IEC-PKS. Post-infusion, pts with IEC-PKS had higher peak ferritin and lower platelet count. ICANS (66 vs 13 vs 6%, p<0.001) and CRS (100 vs 95 vs 58%, p=0.056) were more common in pts with IEC-PKS vs other NINT vs no NINT.
Conclusion: We observed overall low IEC-PKS rates (1.6%) with prophy dex strategy, and these were significantly lower compared to historical data (Prophy dex overall: 1.6%, ALC≥3000: 4%, ALC< 3000: 0%; historical data overall: 2.9%; ALC≥3000: 12%, ALC<3000: 1%; p=0.04 for IEC-PKS in ALC≥3000: 4% vs 12% historical ref Sidana et al. ASH 2025). When implementing prophy dex strategy, dex should be started as soon as ALC meets threshold and be continued until the ALC is reliably below threshold. Additional strategies are needed for ALC non-response to dex. Pre-LD disease burden and ferritin were high in IEC-PKS cases, reinforcing the importance of effective bridging therapy to reduce disease burden to as low as possible prior to cilta-cel. Other measures of disease burden/biology such as low albumin, high B2M and high LDH were also noted in pts with IEC-PKS and are being explored further along with other biomarkers for risk prediction.
DISCLOSURES
Surbhi Sidana, MD: Janssen, BMS, Legend, Arcellx, Kite, Genentech, Roche, Sanofi, Pfizer, Takeda, Kite, Bioline, AbbVie, Cell Centric, Caribou, Regeneron and Eli Lilly (conuslting). Research funding to insitution: Janssen, BMS, Kite, Kelonia, Novartis, Abbvie - Consultancy (Includes expert testimony)